19th Anglonordic Life Science Conference

The 2023 event will take place on 20th April. Please check back here for information, which will be added soon.

Thanks to everyone who came to London to make  Anglonordic's return as an in-person event such a success in 2022: 

260 Attendees
71 Investors
286 Partnering Meetings
26 Startup Pitches

Anglonordic is exclusively for European investors and R&D companies from the Nordics and the UK to connect with each other. With an established format of panel discussions, parallel technology and biotech investment rooms, plus 1:1 meetings, this conference provides exceptional value.

Special thanks to H.E. the Ambassador of Denmark to the UK for hosting the exclusive Anglonordic Drinks Reception at his Central London Residence.

Download the conference brochure Conference brochure download link 


2022 Investors included:
3B Future Health Ventures, 4BIO Capital, ABG Sundal Collier, Advent Life Sciences, Albion Technology & General VCT, Alpha Blue Ocean, Apple Tree Partners, Apposite Capital, Arix Bioscience, Atlas Capital Markets, Axilium Holding AB, Biotechnology Business Institute, Bioqube Ventures, Bootstrap Europe, Cascara Ventures, Cathay Capital, Convergence Partners, CS Life Science Invest, Curam Capital Management, DeBere Capital Partners, Deep Science Ventures, Eli Lilly, Epidarex Capital, Esperante, European Investment Fund, Forbion, Gebro Pharma, GIMV, GL Capital, Global Health Investment Corporation, HealthCap, i2020 Accelerator, Ignite Capital Partners, Industrifonden, Intermediate Capital Group, IP Group, IPF Partners, INKEF Capital, JJDC, Kreos Capital, Kurma Partners, LifeArc Ventures, Limerston Capital Partners, Livzon, MP Healthcare Venture Management, M Ventures, Medicxi, Monograph, MVM, +ND Capital, New Science Global Healthcare Fund, NG Bio, Norgine Ventures, Novo Holdings, o2h Ventures, Optum Ventures, Ovata Capital, Panakes Partners, Parkwalk, Rosetta Capital, Ruffena Capital, RYSE Asset Management, Seventure, Silicon Valley Bank (SVB), Sofinnova Partners, Softbank, Sound Bioventures, Sunstone Life Science Ventures, Syncona, Ventac Partners, Ysios Capital Partners.

Attending Companies

2N Pharma,Ankrin Therapeutics, Argentum, ARJUNA Therapeutics, ARRAYS FOR CELL NANODEVICES, BaseLaunch, BBI Cambridge, BIA, BioCentury, Biogen, BIOHOPE, BioInvent International, BioLucidity Advisors, BioPartner UK, Biotechnology Business Institute, BioWorld, Bit Bio, Brain Tumour Research, Business Region G√∂teborg, Cancerappy, Catherine Moukheibir, Cbio, Civetta Therapeutics, Clarivate, Clive Goddard, CRDN, Curapel, CytoSeek, DNAe, Edity Therapeutics, Eli Lilly and Company, EpiHeart, eTheRNA, Ezenze, FLASH Diagnostics, FreeMind Group, Gadeta, GGS Associates, GIMV, Gr√ľnenthal, GSK, HEI Therapeutics, Helsinn, i2020 Accelerator, Immunicom, Immunorizon, Innovent Biologics, INPROTHER, Intubio, Invizius, JDRF, Kidney Research UK, Laminar Pharma, Leadartis, LEITAT Technological Center, Leucid Bio, Limnopharma, Livzon Pharmaceutical Group, Lytix Biopharma AS, MedCity, Medicon Valley Alliance, Medicxi, MediSieve, MediWales, Meeting Mojo, Melanie Senior, Merck, Merck KGaA, Etain Lavelle, MSD, NanoSyrinx, Newbury Pharmaceuticals, NodThera, Oceanbio, OFX, One Nucleus, Optimum Strategic Communications, Oxford Endovascular, Paras Biopharmaceuticals Finland Oy, PARKINSONGS, Pebmond Associates, Phaim Pharma, Pharma Holdings, Pharmacelera, ProAxsis, Prokarium, PROTEIN ALTERNATIVES REGEMAT3D, Sartar Therapeutics, Scandion Oncology, Senglobal, SomaServe, Stifel, STipe Therapeutics, STORM Therapeutics, Synergia Medical, Techvolver, The Francis Crick Institute, Trobix Bio, University of Oxford, Viramal, Vivesto, Wellthy Therapeutics, Women's Brain Project, Yaqrit, Yorkshire & Humber AHSN.

Anglonordic 2023


Latest social media


(insert image)(insert image)(insert image)(insert image)

Partnering Platform Sponsor